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Abstract. Dacarbazine chemotherapy has been the mainstay 
of melanoma treatment for >30 years. In the early 2000s, 
carboplatin (with or without other agents, such as paclitaxel) 
was the most commonly used second‑line therapy in the 
UK. The aim of the present study was to report a significant 
response rate to second‑line carboplatin in patients from three 
UK institutions who had been previously treated and failed 
to respond to dacarbazine, and investigate whether sequential 
therapy may be more effective compared with combination 
therapy. A total of 104 patients were identified, the majority 
of whom were treated with carboplatin (area under the 
curve 5‑6) every 3 weeks for a maximum of 6 cycles. A total 
of 102 patients were evaluable for response, among whom 
11 patients had an objective response (1 complete response 
and 10 partial responses) and 15 had stable disease, giving 
an overall response rate of 11% and disease control rate of 
26%. The median progression‑free survival was 1.8 months 
(range, 0.2‑36+ months) and the median overall survival was 
4.6 months (range, 0.2‑36+ months). Surprisingly, the majority 
of the patients who benefited from second‑line carboplatin 
therapy were those with visceral metastases, the survival 
of whom would not be expected to exceed 6 months after 
first‑line treatment.
Introduction
The outlook for patients with metastatic melanoma has been 
transformed in the last few years, with >40% of patients 
treated with combination checkpoint inhibitor therapy or 
combination targeted therapy, in case of BRAF‑mutated mela‑
noma, in clinical trials remaining alive after 5 years (1). Novel 
therapies may hold promise in terms of durable remissions, 
but the majority of the patients with melanoma experience 
progression, and some require chemotherapy.
Dacarbazine chemotherapy has been the mainstay of 
melanoma treatment for >30 years. However, the objective 
response (OR) rate was in the order of 10‑20%, and median 
survival was not prolonged (2,3), although some patients 
experienced symptomatic relief, albeit at the cost of limited 
toxicity. There was no standard second‑line therapy, and the 
recommended approach was clinical trials. Patients who were 
unable or unwilling to enter a trial, were considered as possible 
candidates for chemotherapy. In the early 2000s, carboplatin 
(with or without other agents, such as paclitaxel) was the most 
commonly used second‑line agent in the UK (4). The aim of 
the present study was to report the response rate to second‑line 
carboplatin in patients with melanoma from three UK insti‑
tutions who were previously treated and failed to respond to 
dacarbazine, and examine whether sequential therapy may be 
more effective compared with combination therapy. This may 
apply to the incorporation of the newer targeted and immuno‑
therapy treatments available since this study was commenced.
Patients and methods
Patients and approval. Lists of patients treated with 
carboplatin for metastatic melanoma were obtained from 
chemotherapy electronic databases at three tertiary referral 
cancer centres, namely St. George's Hospital (London), 
St. James's University Hospital (Leeds) and Weston Park 
Hospital (Sheffield). The periods covered by the analysis were 
October 2005‑January 2011 for Leeds and Sheffield, and 
November 2009‑September 2015 for St. George's Hospital in 
London. Permission to perform the analysis was granted by 
the local committees of all three hospitals.
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Statistical analysis. Demographic disease‑related and treat‑
ment data were extracted from electronic patient records and 
entered into an Excel spreadsheet. Data were analysed using 
Graph Pad Prism software, version 8.0 (GraphPad Software, 
Inc.).
Results
Patients and treatment. A total of 104 patients were identified 
(49 from St. George's Hospital, 35 from St. James's Hospital 
and 20 from Weston Park Hospital). The patient characteris‑
tics are summarised in Table I. The majority of the patients 
were treated with carboplatin (area under the curve 5‑6) every 
3 weeks for a maximum of 6 cycles. Carboplatin was admin‑
istered as second‑line treatment after documented disease 
progression (no planned switch).
Response to treatment. A total of 102 patients were evaluable for 
response; 11 patients had an OR [complete response (CR), n=1; 
partial response (PR), n=10], and 15 had stable disease (SD), 
with an OR of 11% and disease control rate (CR + PR + SD) of 
26%. Treatment was generally well‑tolerated, with 31 patients 
requiring at least one dose reduction, and 8 patients discon‑
tinuing treatment due to side effects.
Survival. Progression‑free‑survival (PFS) data were available 
for all the patients. Overall survival (OS) data were avail‑
able for 102 patients. All data were censored at 36 months. 
A total of 3 patients remained alive at the time of analysis. 
The median PFS was 1.8 months (range, 0.2‑36+ months) 
and the median OS was 4.6 months (range, 0.2‑36+ months). 
Patients with an Eastern Cooperative Oncology Group 
(ECOG) performance status of 0‑1 had a longer PFS 
(2.1 vs. 1.2 months; P=0.0013 log‑rank test; Fig. 1A) and 
extended median OS (5.0 vs. 2.3 months; P=0.0002; Fig. 1B). 
Patients with normal lactate dehydrogenase (LDH) levels 
prior to commencing treatment with carboplatin also had a 
longer median OS (5.9 vs. 4.5 months; P<0.0071; Fig. 1C). 
Patients who achieved an OR to treatment had a longer median 
OS (4.3 vs. 17.5 months; P=0.0008; Fig. 1D) compared with 
non‑responders.
Discussion
The outlook for patients with metastatic melanoma has 
improved greatly in the last decade. The anti‑CTLA‑4 
monoclonal antibody ipilimumab was the first drug to 
achieve prolongation of survival in patients with metastatic 
melanoma (5). Further improvements have been observed 
with the introduction of the anti‑programmed cell death 
protein 1 (PD1) antibodies pembrolizumab and nivolumab, 
which are more effective and less toxic compared with 
ipilimumab, and with the combination of ipilimumab and 
nivolumab, which achieved an OR rate of 58% (6). Patients 
whose melanomas harbour BRAF mutations also have the 
option of treatment with BRAF inhibitors (vemurafenib 
or dabrafenib), or with combinations of BRAF and MEK 
inhibitors (dabrafenib with trametinib, or encorafenib with 
binimetinib). The OR with single‑agent BRAF inhibitor 
was ~55%, compared with 68% in patients on combination 
therapy (7). Over half of the patients treated with combina‑
tion therapies remained alive at 3 years (6,7).
Despite these advances, it is likely that most patients with 
metastatic melanoma will relapse. A number of patients are not 
suitable for combination therapy, others are unable to receive 
immunotherapy due to pre‑existing autoimmune conditions, 
and 60% of melanomas are wild‑type for BRAF (8). These 
patients may still require treatment, and it is therefore impor‑
tant to assess pre‑existing therapies and evaluate previous 
experience. To the best of our knowledge, the present review 
of 104 consecutive patients in three centres who were treated 
with carboplatin for metastatic melanoma is the largest 
such series to date. In our cohorts of patients, response and 
disease stabilisation were observed, with no unexpected 
complications. Patients with an ECOG performance status 
of 0‑1, normal levels of LDH, and those who achieved an 
OR, exhibited a significantly longer OS, in keeping with the 
data in the literature (9,10). Surprisingly, the majority of the 
Table I. Patient demographics prior to commencing treatment 
with carboplatin (n=104).
Variables No.
Median age, years (range) 61 (23‑89)
Eastern Cooperative Oncology 
Group performance status
  0 48
  1 28
  2 13
  3 3
  Unknown 12
Primary melanoma location 
  Skin  91
  Mucosal  2
  Ocular  9
  Unknown 2
American Joint Committee on Cancer 
stage (version 7)
  III 16
  IV 88
Baseline lactate dehydrogenase 
  Normal 48
  Elevated 52
  Not recorded 4
First‑line regimen 
  Single‑agent dacarbazine  85
  Temozolomide 4
  Dacarbazine in combination with other agents 15
Best response to first‑line treatment  
  Complete response 0
  Partial response 12
  Stable disease 14
  Progressive disease 76
  Not recorded 2
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patients who benefited from second‑line carboplatin therapy 
were those with visceral distant metastases, the survival 
of whom would not be expected to exceed 6 months after 
first‑line treatment. Dacarbazine plus cisplatin or carboplatin, 
when given together, appear to have no synergistic benefit (11), 
and it is unclear whether dacarbazine exerts any significant 
effect on the susceptibility of tumour cells to carboplatin, or 
whether there is an indirect effect on the microenvironment 
or the immune response. It is therefore of great interest that 
a small but true benefit was observed with the sequential 
use of these agents, where the overall clinical benefit of 26% 
is notably higher compared with that reported by several 
first‑line studies (2,3). It is particularly important, given that 
there appears to be a concern that multiple drug combinations 
may achieve better response rates, but do not affect the overall 
outcome or survival. Of the 3 patients who remain alive 
and who had an OR to treatment, 2 also received a course 
of low‑dose interleukin‑2 post‑carboplatin, which may also 
suggest a type of synergy of the sequential treatment (12).
In conclusion, the observations of the present study may 
provide a rationale for exploring the potential of carboplatin in 
patients with failure of targeted treatment and immunotherapy, 
and for other treatments to be used sequentially rather than 
concurrently, where the only definitive outcome that can be 
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Figure 1. (A and B) PFS and OS in patients treated with carboplatin according to ECOG performance status score (0‑1 vs. >1). OS according to (C) the levels of 
LDH (normal vs. elevated) and (D) the objective response to treatment (PR + CR vs. SD + PD). OS, overall survival; PFS, progression‑free survival; ECOG, Eastern 
Cooperative Oncology Group; LDH, lactate dehydrogenase; PR, partial response; CR, complete response; D, stable disease; PD, progressive disease.
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